ADIL Financials: Adial Pharmaceuticals Inc AI Analysis

Home

Stock

ADIL

Financials

ADIL Financial

Adial Pharmaceuticals Inc

$1.72

-0.57%

$-0.01

At close: Mar 26, 16:00:00 GMT-4

$1.72

Pre-market: Mar 27, 04:05:05 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

ADIL Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	5	5	5	5	9	9
Research & Development	2	2	3	1	4	8
Operating Expenses	7	7	8	6	13	17
Other Non Operating Income (Expenses)	0	0	-4	0	0	0
Pretax Income	-7	-7	-13	-7	-12	-19
Income Tax Expense	--	--	0	0	0	0
Net Income	-7	-7	-13	-5	-12	-19
Net Income Growth	-46%	-46%	160%	-57.99%	-37%	90%
Shares Outstanding (Diluted)	1.09	0.66	0.19	0.05	1	0.74
Shares Change (YoY)	-83%	244%	241%	-94%	35%	48%
EPS (Diluted)	-7.29	-11.93	-68	-89.89	-12.71	-26.24
EPS Growth	256%	-82%	-24%	607%	-52%	20%
Free Cash Flow	-6	-6	-6	-6	-11	-12
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-7	-7	-8	-6	-13	-17
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-7	-7	-8	-6	-13	-17
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	0%	0%	0%	0%

Follow-Up Questions

What are Adial Pharmaceuticals Inc's key financial statements?



According to the latest financial statement (Form-10K), Adial Pharmaceuticals Inc has a total asset of $6, Net loss of $-7

What are the key financial ratios for ADIL?



Adial Pharmaceuticals Inc's Current ratio is 6, has a Net margin is 0, sales per share of $0.

How is Adial Pharmaceuticals Inc's revenue broken down by segment or geography?



Adial Pharmaceuticals Inc largest revenue segment is Oil and Gas, at a revenue of 1,082,018 in the most earnings release.For geography, United States is the primary market for Adial Pharmaceuticals Inc, at a revenue of 857,855.

Is Adial Pharmaceuticals Inc profitable?



no, according to the latest financial statements, Adial Pharmaceuticals Inc has a net loss of $-7

Does Adial Pharmaceuticals Inc have any liabilities?



yes, Adial Pharmaceuticals Inc has liability of 1

How many outstanding shares for Adial Pharmaceuticals Inc?



Adial Pharmaceuticals Inc has a total outstanding shares of 1.11

Key Stats

Prev.Close

$1.73

Open

$1.75

Day's Range

$1.72 - $1.78

52 week range

$1.54 - $30.25

Volume

68.0K

Avg.Volume

78.1K

Dividend yield

EPS (TTM)

-15.47

Market Cap

$1.9M

What is ADIL?

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.



Features

AI Copilot for Stock & Crypto

Resources